This topic contains a solution. Click here to go to the answer

Author Question: For the best therapeutic effect after a myocardial infarction (MI), thrombolytics should be ... (Read 33 times)

audragclark

  • Hero Member
  • *****
  • Posts: 579
For the best therapeutic effect after a myocardial infarction (MI), thrombolytics should be administered within the first 3 hours (ideally 30 minutes) of presentation of symptoms.
 
  Studies have shown that thrombolytic therapy, however, can be of benefit up to how many hours after the initial presentation of symptoms of MI?
  a. 6 hours c. 10 hours
  b. 8 hours d. 12 hours

Question 2

What percentage of patients with angina pectoris will have simultaneous dyspnea, caused by transient increase in pulmonary venous pressures that accompany ventricular stiffening during an episode of myocardial ischemia?
 
  a. About 20 c. About 50
  b. About 30 d. Almost all



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

wilsonbho

  • Sr. Member
  • ****
  • Posts: 322
Answer to Question 1

D

Answer to Question 2

B




audragclark

  • Member
  • Posts: 579
Reply 2 on: Jul 22, 2018
:D TYSM


bbburns21

  • Member
  • Posts: 336
Reply 3 on: Yesterday
Great answer, keep it coming :)

 

Did you know?

The top five reasons that children stay home from school are as follows: colds, stomach flu (gastroenteritis), ear infection (otitis media), pink eye (conjunctivitis), and sore throat.

Did you know?

Oliver Wendell Holmes is credited with introducing the words "anesthesia" and "anesthetic" into the English language in 1846.

Did you know?

Though “Krazy Glue” or “Super Glue” has the ability to seal small wounds, it is not recommended for this purpose since it contains many substances that should not enter the body through the skin, and may be harmful.

Did you know?

More than 2,500 barbiturates have been synthesized. At the height of their popularity, about 50 were marketed for human use.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

For a complete list of videos, visit our video library